Efficacy and safety of filgotinib as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a post-hoc analysis of the phase 2b/3 SELECTION trial

BACKGROUND/AIMS: The safety and efficacy of filgotinib, a once-daily oral Janus kinase 1 preferential inhibitor, were evaluated in Japanese patients with ulcerative colitis (UC) in the phase 2b/3 SELECTION trial. METHODS: SELECTION (NCT02914522) was a randomized, placebo-controlled trial comprising...

Descripción completa

Detalles Bibliográficos
Autores principales: Hibi, Toshifumi, Motoya, Satoshi, Hisamatsu, Tadakazu, Hirai, Fumihito, Watanabe, Kenji, Matsuoka, Katsuyoshi, Saruta, Masayuki, Kobayashi, Taku, Feagan, Brian G, Tasset, Chantal, Besuyen, Robin, Yun, Chohee, Crans, Gerald, Zhang, Jie, Kondo, Akira, Watanabe, Mamoru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Association for the Study of Intestinal Diseases 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9911269/
https://www.ncbi.nlm.nih.gov/pubmed/35263963
http://dx.doi.org/10.5217/ir.2021.00143

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9911269/
https://www.ncbi.nlm.nih.gov/pubmed/35263963
http://dx.doi.org/10.5217/ir.2021.00143

Ejemplares similares